American Shared Hospital Services

American Shared Hospital Services (AMS) Stock Analysis

$1.470

+0.010 (+0.68%)At close

Loading chart…
High
1.470
Open
1.442
VWAP
1.46
Vol
2.89K
Mkt Cap
20.46M
Low
1.442
Amount
4.22K
EV/EBITDA, TTM
0.00

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.

ashs.com

AI analysis of American Shared Hospital Services (AMS)

hold

American Shared Hospital Services is not a strong buy at this moment due to a current price of $1.47, a year-to-date change of -30.08%, and a forward P/E ratio of 44.64, indicating high valuation despite recent revenue growth. The main risk is the net loss of $998,000 reported in Q2 2026, which raises concerns about financial stability.

Valuation Metrics

The current forward P/E ratio for American Shared Hospital Services (AMS) is 44.64, compared to its 5-year average forward P/E of 12.18.

Forward P/E

Overvalued
5Y Average P/E
12.18
Current P/E
44.64
Overvalued
37.27
Undervalued
-12.92

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Undervalued
5Y Average P/S
0.46
Current P/S
0.00
Overvalued
0.79
Undervalued
0.14

Alphio AI Price Scenarios for AMS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AMS

$3.00

Scenario price

B

Base

Base · 50%AMS

$2.96

Scenario price

B

Bear

Bear · 25%AMS

$2.19

Scenario price

Events Timeline

2025-12-01 (ET)

05:29:00

JPMorgan Downgrades ams OSRAM to Underweight, Price Target Cut to CHF 5.35

2025-11-13 (ET)

07:04:59

American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year

2025-08-13 (ET)

07:07:11

American Shared Hospital reports Q2 EPS (4c) vs. 55c last year

2025-05-15 (ET)

07:02:10

American Shared Hospital reports Q1 EPS (10c) vs 2c last year

2025-04-04 (ET)

07:04:18

American Shared Hospital appoints Gary Delanois as CEO

News

AMS FAQ — answered by Alphio AI

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally. It operates in the Industrials sector (SERVICES-MEDICAL LABORATORIES industry).

American Shared Hospital Services is not a strong buy at this moment due to a current price of $1.47, a year-to-date change of -30.08%, and a forward P/E ratio of 44.64, indicating high valuation despite recent revenue growth. The main risk is the net loss of $998,000 reported in Q2 2026, which raises concerns about financial stability.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める